.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Novartis
Colorcon
Queensland Health
Merck
Boehringer Ingelheim
Accenture
Cantor Fitzgerald
Cerilliant
Johnson and Johnson
Covington

Generated: November 17, 2017

DrugPatentWatch Database Preview

ALIMTA Drug Profile

« Back to Dashboard

What is the patent landscape for Alimta, and what generic Alimta alternatives are available?

Alimta is a drug marketed by Lilly and is included in one NDA. There are two patents protecting this drug and four Paragraph IV challenges.

This drug has thirty-one patent family members in twenty-five countries and six supplementary protection certificates in six countries.

The generic ingredient in ALIMTA is pemetrexed disodium. There are twenty-eight drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pemetrexed disodium profile page.
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-002Sep 7, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-001Feb 4, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-002Sep 7, 2007RXYesYes► Subscribe► SubscribeY► Subscribe
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-001Feb 4, 2004RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ALIMTA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-002Sep 7, 2007► Subscribe► Subscribe
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-001Feb 4, 2004► Subscribe► Subscribe
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-002Sep 7, 2007► Subscribe► Subscribe
Lilly
ALIMTA
pemetrexed disodium
INJECTABLE;IV (INFUSION)021462-001Feb 4, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ALIMTA

Drugname Dosage Strength RLD Submissiondate
pemetrexed disodiumFor Injection750 mg/vialAlimta10/6/2016
pemetrexed disodiumFor Injection1000 mg/vialAlimta6/27/2012
pemetrexed disodiumFor Injection100 mg/vialAlimta7/1/2008
pemetrexed disodiumFor Injection500 mg/vialAlimta2/4/2008

Non-Orange Book Patents for Tradename: ALIMTA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
4,996,206 N-(pyrrolo[2,3-d]pyrimidin-3-ylacyl)-glutamic acid derivatives► Subscribe
5,248,775 Pyrrolo(2,3-d)pyrimidines► Subscribe
5,028,608 N-(6-Amino-(pyrrolo(2,3-d)pyrimidin-3-ylacyl) )-glutamic acid derivatives► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ALIMTA

Country Document Number Estimated Expiration
European Patent Office0432677► Subscribe
Netherlands300181► Subscribe
Luxembourg91147► Subscribe
Australia6779190► Subscribe
South Africa9009631► Subscribe
Hungary218483► Subscribe
China1055182► Subscribe
Canada2031890► Subscribe
Spain2084639► Subscribe
Austria135007► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALIMTA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0432677/01Switzerland► SubscribeFORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
147Luxembourg► Subscribe91147, EXPIRES: 20151210
C/GB05/011United Kingdom► SubscribePRODUCT NAME: PEMETREXED AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/04/290/001 20040920
0181Netherlands► Subscribe300181, 20101210, EXPIRES: 20151209
2005 00008Denmark► Subscribe
2005Austria► SubscribePRODUCT NAME: PEMETREXED UND DESSEN PHARMAZEUTISCH ANNAHMBAREN SALZE; REGISTRATION NO/DATE: EU/1/04/290/001 20040920
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Julphar
Johnson and Johnson
Dow
US Army
Merck
Fish and Richardson
Teva
Daiichi Sankyo
Cipla
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot